A platform study exploring the safety tolerability effects on the tumor microenvironment and efficacy of Pembroliumab (MK-3475) + INCB combination
Clinical Trial Grant
Awarded By
Incyte Corporation
Start Date
May 1, 2016
End Date
May 1, 2021
Awarded By
Incyte Corporation
Start Date
May 1, 2016
End Date
May 1, 2021